Analytical Data
-
Gene name
MIP1a
- Application
-
Alternative Names
CCL3; MIP1-A; SCYA3; Chemokine C-C-Motif Ligand 3; Small Inducible Cytokine A3; Homologous To Mouse Mip-1a; Tonsillar Lymphocyte LD78 Alpha Protein
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10855
-
Expression Region
Ala24~Ala92
-
Molecular Weight
15kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIP-1α, also known as CCL3, is a chemokine that plays a crucial role in the immune response by attracting immune cells to sites of inflammation and infection. Its importance is underscored by its involvement in various physiological and pathological processes, including allergic reactions, tissue repair, and the progression of diseases such as HIV infection and cancer. The research on recombinant MIP-1α protein focuses on its potential applications in immunotherapy and vaccine development. By producing MIP-1α in a recombinant form, researchers aim to study its structure-function relationship, enhance understanding of its signaling pathways, and explore its therapeutic potential. Recombinant MIP-1α can be used to investigate its role in modulating immune responses and to develop novel therapeutic strategies that utilize its ability to recruit specific immune cell populations. Additionally, the production of MIP-1α in a laboratory setting allows for detailed study of its interactions with other immune mediators and its effects on various cell types, paving the way for innovative treatments for inflammatory diseases and infectious conditions. Understanding the molecular mechanisms underlying the function of recombinant MIP-1α may ultimately contribute to the development of targeted therapies that harness the body’s immune system to fight diseases more effectively.
